NSE: RPGLIFE | BSE: 532983

Mid-range Performer

Download real time

2004.90 -32.40 (-1.59%)

26.43% Fall from 52W High

5,805 NSE+BSE Volume

NSE 12 Feb, 2026 3:31 PM (IST)

3,315.9

Market Cap

Above industry Median

Beta 1Year

Average volatility

RPG Life Sciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for RPGLIFE, BSE:532983 RPG Life Sciences Ltd.

Search Inside the pdf :

RPG Life Sciences Ltd.

29 Jan 2026

2004.90

-1.59%

About the company- RPG Life Sciences RPGLS (part of RPG Group) is a pharmaceutical company that operates in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company...

ICICI Direct released a Buy report for RPG Life Sciences Ltd. with a price target of 2470.0 on 29 Jan, 2026.

RPG Life Sciences Ltd.

16 Jun 2023

2004.90

-1.59%

RPG Life Sciences (NOT RATED): Investor day takeaways Foundation in place; now targeting scale

Not Rated: RPG Life Sciences Ltd.

BOB Capital Markets Ltd.

FY23 a milestone year with revenue/EBITDA of Rs 500mn/100mn; Naprosyn brand crossed Rs 500mn

RPG Life Sciences Ltd. has an average target of 2470.00 from 1 broker.

RPG Life Sciences Ltd.

18 Jan 2023

2004.90

-1.59%

TECHNO FUNDA - RPG LIFE SCIENCES

Buy: RPG Life Sciences Ltd.

Chola Wealth Direct

RPG Life Sciences Ltd. is trading below all available SMAs

RPG Life Sciences Ltd.

16 Sep 2022

2004.90

-1.59%

RPG Life Sciences (NOT RATED): Investor day takeaways Chronic and specialty launch focus

Not Rated: RPG Life Sciences Ltd.

BOB Capital Markets Ltd.

EBITDA margin up 10ppt from FY19 levels to ~20% in FY22 as efforts to improve operational efficiency pay off

ICICI Direct released a Buy report for RPG Life Sciences Ltd. with a price target of 2470.0 on 29 Jan, 2026.

RPG Life Sciences Ltd.

18 Jun 2021

2004.90

-1.59%

RPG Life Sciences (NOT RATED): Annual investor conference takeaways

Not Rated: RPG Life Sciences Ltd.

BOB Capital Markets Ltd.

RPGL reported revenue growth, margin expansion and debt reduction in FY21 despite Covid-led disruptions in the acute portfolio

Number of FII/FPI investors decreased from 67 to 60 in Dec 2025 qtr

RPG Life Sciences Ltd.

15 Jun 2018

2004.90

-1.59%

Management Visit Note of RPG Life Sciences

Mgmt Note: RPG Life Sciences Ltd.

IDBI Capital

We recently met the management of RPG Life sciences (RPG). RPG is primarily engaged in manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs or bulk actives). RPG specializes in therapeutic areas like nephrology, oncology, urology, gastroenterology, pain management and nutritionals. RPG enjoys a strong brand recognition in anti-diarrheal, antacid, iron-vitamin, and nephrology segments. Domestic formulation 19% revenue growth YoY RPG has its manufacturing facilities in 1) Maharashtra and 2) Gujarat. RPG continues to strive to be a dominant player in specialty by focusing on differentiated products....

RPG Life Sciences Ltd. is trading below all available SMAs

RPG Life Sciences Ltd.

23 Jan 2017

2004.90

-1.59%

Visit Note on RPG Life Sciences Ltd

Mgmt Note: RPG Life Sciences Ltd.

IDBI Capital

RPG Life Sciences Ltd (RPG), formally known as Searle India was incorporated in 1968 as a pharmaceuticals and agrochemicals business, however, divested the agrochemicals in 2001 and renamed as RPG Phamaceuticals Ltd, HQ in Mumbai which is primarily engaged in manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs or bulk actives). RPG specializes in therapeutic areas like nephrology, oncology gastroenterology, pain management and nutritionals. RPG is ranked 66th (Source: Pharmatrac) in the domestic formulations market and ranks among the top 5 Indian companies in the renal therapy segment. Domestic market accounts for ~67% of revenues while the main:specialty ratio is at 60:40. The company has...

ICICI Direct released a Buy report for RPG Life Sciences Ltd. with a price target of 2470.0 on 29 Jan, 2026.

RPG Life Sciences Ltd.

19 Dec 2016

2004.90

-1.59%

Pick of the Week - RPG Life Sciences

Buy: RPG Life Sciences Ltd.

HDFC Securities

BUY RPG Life Sciences at CMP Rs.469 and add on Declines to Rs.435 - 408 for sequential target of Rs. 545, 658

ICICI Direct released a Buy report for RPG Life Sciences Ltd. with a price target of 2470.0 on 29 Jan, 2026.

RPG Life Sciences Ltd.

27 Sep 2013

2004.90

-1.59%

RPG Lifesciences

Buy: RPG Life Sciences Ltd.

Ajcon Global

RPG Life Sciences Ltd. is an integrated Pharmaceutical Company operating in the domestic and international markets in the Branded Formulations, Global Generics, Synthetic and Fermentation API's space. The Company is a research based Pharmaceutical Company, producing a wide range of quality, affordable medicines and exports to Europe, Latin America, Canada and South East Asian Countries. In Q1FY14, the Company's turnover witnessed yoy growth of 15 percent to touch...

Number of FII/FPI investors decreased from 67 to 60 in Dec 2025 qtr

Is RPG Life Sciences Ltd. worth buying?

84 Votes:

Buy 72.62%

Sell 17.86%

Hold 9.52%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf